Press Releases

Centessa Pharmaceuticals to Participate in Upcoming Investor Conferences

BOSTON and LONDON, Oct. 31, 2022 (GLOBE NEWSWIRE) — Centessa Pharmaceuticals plc (Nasdaq: CNTA), a clinical-stage pharmaceutical company that aims to discover and develop medicines that are transformational for patients, today announced that members of its management team will participate in the following investor conferences:

Event: Jefferies London Healthcare Conference
Date: Thursday, November 17, 2022
Location: London, UK
Fireside Chat: 10:55 AM GMT

Event: Evercore ISI HealthCONx Conference (Virtual)
Date: Wednesday, November 30, 2022
Fireside Chat: 3:30 PM ET

Access to the live webcasts of these events, as well as archived recordings, will be available under the “Events and Publications” tab on the investor relations section of the Centessa Pharmaceuticals website at https://investors.centessa.com/events-presentations.

About Centessa Pharmaceuticals 
Centessa Pharmaceuticals plc is a clinical-stage pharmaceutical company that aims to discover and develop medicines that are transformational for patients. Our programs span discovery-stage to late-stage development and cover a range of high-value indications in rare diseases and immuno-oncology. We operate with the conviction that each one of our programs has the potential to change the current treatment paradigm and establish a new standard of care. For more information, visit www.centessa.com, which does not form part of this release. 

Contact:
Kristen K. Sheppard, Esq.
SVP of Investor Relations
investors@centessa.com

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More